BLSM

SEC source: 0001840599-26-000003 · form4-08102026_100855.xml · derivative · entry 3

Agrawal Sundeep · CIK 0001840599 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Brahma BlossomHill Partners, LLC

Disclosed balance after: 0

Underlying: Common Stock · 578,524 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · price: Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: The securities are held of record by Brahma BlossomHill Partners, LLC ("Brahma Partners"). The Reporting Person is the founder and managing partner of Brahma Capital, LLC, which manages Brahma Partners, and may be deemed to have sole voting and/or investment power over the securities held by Brahma Partners. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

SEC source: 0001840599-26-000003 · form4-08102026_100855.xml · nonDerivative · entry 1

Agrawal Sundeep · CIK 0001840599 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Brahma BlossomHill Partners, LLC

Disclosed balance after: 578,524

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: The securities are held of record by Brahma BlossomHill Partners, LLC ("Brahma Partners"). The Reporting Person is the founder and managing partner of Brahma Capital, LLC, which manages Brahma Partners, and may be deemed to have sole voting and/or investment power over the securities held by Brahma Partners. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

SEC source: 0001478916-26-000015 · form4-08102026_100806.xml · nonDerivative · entry 1

Schmid John P. · CIK 0001478916 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

SEC source: 0001678152-26-000003 · form4-08102026_100815.xml · nonDerivative · entry 1

Keyes Jason A · CIK 0001678152 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 700

SEC source: 0001231919-26-000852 · form4-08102026_100859.xml · derivative · entry 6

Chen Bihua · CIK 0001599214 · Director · 10% owner

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner

Cormorant Private Healthcare Fund V LP · CIK 0001969296 · 10% owner

Cormorant Private Healthcare Fund VI, LP · CIK 0002098185 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 1,701,541 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2 · price: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F5 · derivative.underlying_shares: Represents (i) 274,912 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Master Fund, (ii) 1,052,460 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund V and (iii) 374,169 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund VI.

F3 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund V, LP ("Fund V") and Cormorant Private Healthcare Fund VI, LP ("Fund VI"). Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP III, LLC ("GP III"), Cormorant Private Healthcare GP V, LLC ("GP V") and Cormorant Private Healthcare GP VI, LLC ("GP VI") serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively.

F4 · ownership.nature: Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0001231919-26-000852 · form4-08102026_100859.xml · derivative · entry 5

Chen Bihua · CIK 0001599214 · Director · 10% owner

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner

Cormorant Private Healthcare Fund V LP · CIK 0001969296 · 10% owner

Cormorant Private Healthcare Fund VI, LP · CIK 0002098185 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 1,599,993 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2 · price: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · derivative.underlying_shares: Represents (i) 1,228,315 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Fund III (defined below), and (ii) 371,678 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Master Fund (defined below).

F3 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund V, LP ("Fund V") and Cormorant Private Healthcare Fund VI, LP ("Fund VI"). Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP III, LLC ("GP III"), Cormorant Private Healthcare GP V, LLC ("GP V") and Cormorant Private Healthcare GP VI, LLC ("GP VI") serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively.

F4 · ownership.nature: Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0001231919-26-000852 · form4-08102026_100859.xml · nonDerivative · entry 3

Chen Bihua · CIK 0001599214 · Director · 10% owner

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner

Cormorant Private Healthcare Fund V LP · CIK 0001969296 · 10% owner

Cormorant Private Healthcare Fund VI, LP · CIK 0002098185 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 3,614,034

F7 · shares: The shares purchased are beneficially owned by Master Fund.

F8 · balance_after: Represents an aggregate of (i) 959,090 shares beneficially owned by Master Fund, (ii) 1,228,315 shares beneficially owned by Fund III, (iii) 1,052,460 shares beneficially owned by Fund V, and (vi) 374,169 beneficially owned by Fund VI.

F3 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund V, LP ("Fund V") and Cormorant Private Healthcare Fund VI, LP ("Fund VI"). Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP III, LLC ("GP III"), Cormorant Private Healthcare GP V, LLC ("GP V") and Cormorant Private Healthcare GP VI, LLC ("GP VI") serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively.

F4 · ownership.nature: Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0001231919-26-000852 · form4-08102026_100859.xml · nonDerivative · entry 2

Chen Bihua · CIK 0001599214 · Director · 10% owner

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner

Cormorant Private Healthcare Fund V LP · CIK 0001969296 · 10% owner

Cormorant Private Healthcare Fund VI, LP · CIK 0002098185 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 3,301,534

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · shares: Represents (i) 274,912 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Master Fund, (ii) 1,052,460 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund V and (iii) 374,169 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund VI.

F2 · price: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F6 · balance_after: Represents an aggregate of (i) 646,590 shares beneficially owned by Master Fund, (ii) 1,228,315 shares beneficially owned by Fund III, (iii) 1,052,460 shares beneficially owned by Fund V, and (vi) 374,169 beneficially owned by Fund VI.

F3 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund V, LP ("Fund V") and Cormorant Private Healthcare Fund VI, LP ("Fund VI"). Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP III, LLC ("GP III"), Cormorant Private Healthcare GP V, LLC ("GP V") and Cormorant Private Healthcare GP VI, LLC ("GP VI") serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively.

F4 · ownership.nature: Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0001231919-26-000852 · form4-08102026_100859.xml · nonDerivative · entry 1

Chen Bihua · CIK 0001599214 · Director · 10% owner

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner

Cormorant Private Healthcare Fund V LP · CIK 0001969296 · 10% owner

Cormorant Private Healthcare Fund VI, LP · CIK 0002098185 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,599,993

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents (i) 1,228,315 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Fund III (defined below), and (ii) 371,678 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Master Fund (defined below).

F2 · price: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · balance_after: Represents (i) 1,228,315 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Fund III (defined below), and (ii) 371,678 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Master Fund (defined below).

F3 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund V, LP ("Fund V") and Cormorant Private Healthcare Fund VI, LP ("Fund VI"). Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP III, LLC ("GP III"), Cormorant Private Healthcare GP V, LLC ("GP V") and Cormorant Private Healthcare GP VI, LLC ("GP VI") serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively.

F4 · ownership.nature: Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0002143905-26-000003 · form4-08102026_100801.xml · derivative · entry 5

Liptak Vincent Paul · CIK 0002143905 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Indirect · By Walter T. Liptak Revocable Trust

Disclosed balance after: 0

Underlying: Common Stock · 22,687 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · price: Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: The Reporting Person is a co-beneficiary and co-trustee of the Walter T. Liptak Revocable Trust (the "Trust") and has voting and dispositive power over the securities held by the Trust.

SEC source: 0002143905-26-000003 · form4-08102026_100801.xml · nonDerivative · entry 3

Liptak Vincent Paul · CIK 0002143905 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Indirect · By Walter T. Liptak Revocable Trust

Disclosed balance after: 22,687

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: The Reporting Person is a co-beneficiary and co-trustee of the Walter T. Liptak Revocable Trust (the "Trust") and has voting and dispositive power over the securities held by the Trust.

SEC source: 0002143905-26-000003 · form4-08102026_100801.xml · nonDerivative · entry 2

Liptak Vincent Paul · CIK 0002143905 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,412

SEC source: 0001772233-26-000005 · form4-08102026_100812.xml · derivative · entry 9

Li Yishan · CIK 0001772233 · Director · Executive Chairman · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By RongShan, LLC

Disclosed balance after: 0

Underlying: Common Stock · 124,779 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F3 · ownership.nature: The Reporting Person is manager of RongShan, LLC and may be deemed to have voting and dispositive power over the securities held by RongShan.LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

SEC source: 0001772233-26-000005 · form4-08102026_100812.xml · derivative · entry 8

Li Yishan · CIK 0001772233 · Director · Executive Chairman · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Li and Cui Family Trust

Disclosed balance after: 0

Underlying: Common Stock · 113,435 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust.

SEC source: 0001772233-26-000005 · form4-08102026_100812.xml · derivative · entry 7

Li Yishan · CIK 0001772233 · Director · Executive Chairman · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Li and Cui Family Trust

Disclosed balance after: 0

Underlying: Common Stock · 1,600,682 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust.

SEC source: 0001772233-26-000005 · form4-08102026_100812.xml · nonDerivative · entry 3

Li Yishan · CIK 0001772233 · Director · Executive Chairman · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By RongShan, LLC

Disclosed balance after: 124,779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F3 · ownership.nature: The Reporting Person is manager of RongShan, LLC and may be deemed to have voting and dispositive power over the securities held by RongShan.LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

SEC source: 0001772233-26-000005 · form4-08102026_100812.xml · nonDerivative · entry 2

Li Yishan · CIK 0001772233 · Director · Executive Chairman · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Li and Cui Family Trust

Disclosed balance after: 1,714,117

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust.

SEC source: 0001772233-26-000005 · form4-08102026_100812.xml · nonDerivative · entry 1

Li Yishan · CIK 0001772233 · Director · Executive Chairman · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Li and Cui Family Trust

Disclosed balance after: 1,600,682

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust.

SEC source: 0001772259-26-000005 · form4-08102026_100800.xml · derivative · entry 9

Cui Jingrong Jean · CIK 0001772259 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By RongShan, LLC

Disclosed balance after: 0

Underlying: Common Stock · 124,779 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F3 · ownership.nature: The Reporting Person's spouse is the manager of RongShan, LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

SEC source: 0001772259-26-000005 · form4-08102026_100800.xml · derivative · entry 8

Cui Jingrong Jean · CIK 0001772259 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Li and Cui Family Trust

Disclosed balance after: 0

Underlying: Common Stock · 113,435 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust.

SEC source: 0001772259-26-000005 · form4-08102026_100800.xml · derivative · entry 7

Cui Jingrong Jean · CIK 0001772259 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Li and Cui Family Trust

Disclosed balance after: 0

Underlying: Common Stock · 1,600,682 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust.

SEC source: 0001772259-26-000005 · form4-08102026_100800.xml · nonDerivative · entry 3

Cui Jingrong Jean · CIK 0001772259 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By RongShan, LLC

Disclosed balance after: 124,779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F3 · ownership.nature: The Reporting Person's spouse is the manager of RongShan, LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

SEC source: 0001772259-26-000005 · form4-08102026_100800.xml · nonDerivative · entry 2

Cui Jingrong Jean · CIK 0001772259 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Li and Cui Family Trust

Disclosed balance after: 1,714,117

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust.

SEC source: 0001772259-26-000005 · form4-08102026_100800.xml · nonDerivative · entry 1

Cui Jingrong Jean · CIK 0001772259 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Li and Cui Family Trust

Disclosed balance after: 1,600,682

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust.

SEC source: 0000947871-26-000784 · ownership.xml · derivative · entry 5

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 1,049,283 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.

F3 · ownership.nature: These securities are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-26-000784 · ownership.xml · derivative · entry 4

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 1,039,996 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.

F3 · ownership.nature: These securities are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-26-000784 · ownership.xml · nonDerivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 2,714,279

F2 · shares: Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.

F3 · ownership.nature: These securities are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-26-000784 · ownership.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 2,089,279

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.

F3 · ownership.nature: These securities are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-26-000784 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,039,996

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.

F3 · ownership.nature: These securities are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-26-000785 · ownership.xml · derivative · entry 5

GORDON CARL L · CIK 0001282930 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 1,049,283 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.

F3 · ownership.nature: These securities are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-26-000785 · ownership.xml · derivative · entry 4

GORDON CARL L · CIK 0001282930 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 1,039,996 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.

F3 · ownership.nature: These securities are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-26-000785 · ownership.xml · nonDerivative · entry 3

GORDON CARL L · CIK 0001282930 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 2,714,279

F2 · shares: Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.

F3 · ownership.nature: These securities are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-26-000785 · ownership.xml · nonDerivative · entry 2

GORDON CARL L · CIK 0001282930 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 2,089,279

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.

F3 · ownership.nature: These securities are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-26-000785 · ownership.xml · nonDerivative · entry 1

GORDON CARL L · CIK 0001282930 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,039,996

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.

F3 · ownership.nature: These securities are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0002143905-26-000003 · form4-08102026_100801.xml · nonDerivative · entry 1

Liptak Vincent Paul · CIK 0002143905 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,212

SEC source: 0001840599-26-000003 · form4-08102026_100855.xml · derivative · entry 2

Agrawal Sundeep · CIK 0001840599 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,904

Underlying: Common Stock · 23,904 shares

Expires 2036-08-05

F3 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest in equal monthly installments over a three year period following August 6, 2026.

SEC source: 0001282930-26-000008 · form4-08102026_100839.xml · derivative · entry 1

GORDON CARL L · CIK 0001282930 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,904

Underlying: Common Stock · 23,904 shares

Expires 2036-08-05

F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest in equal monthly installments over a three year period following August 6, 2026.

F2 · ownership.direct: Pursuant to an agreement with OrbiMed Advisors LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof to OrbiMed Advisors LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP.

SEC source: 0001678152-26-000003 · form4-08102026_100815.xml · derivative · entry 2

Keyes Jason A · CIK 0001678152 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,746

Underlying: Common Stock · 56,746 shares

Expires 2036-08-05

F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months.

SEC source: 0001231919-26-000852 · form4-08102026_100859.xml · derivative · entry 4

Chen Bihua · CIK 0001599214 · Director · 10% owner

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner

Cormorant Private Healthcare Fund V LP · CIK 0001969296 · 10% owner

Cormorant Private Healthcare Fund VI, LP · CIK 0002098185 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,904

Underlying: Common Stock · 23,904 shares

Expires 2036-08-05

F9 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest in equal monthly installments over a three year period following August 6, 2026.

SEC source: 0002143905-26-000003 · form4-08102026_100801.xml · derivative · entry 4

Liptak Vincent Paul · CIK 0002143905 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,561

Underlying: Common Stock · 46,561 shares

Expires 2036-08-05

F3 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months.

SEC source: 0002144320-26-000003 · form4-08102026_100847.xml · derivative · entry 1

Oxnard Geoffrey Raymond · CIK 0002144320 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,783

Underlying: Common Stock · 61,783 shares

Expires 2036-08-05

F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months.

SEC source: 0001772233-26-000005 · form4-08102026_100812.xml · derivative · entry 6

Li Yishan · CIK 0001772233 · Director · Executive Chairman · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,701

Underlying: Common Stock · 112,701 shares

Expires 2036-08-05

F4 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months.

SEC source: 0001772259-26-000005 · form4-08102026_100800.xml · derivative · entry 6

Cui Jingrong Jean · CIK 0001772259 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 676,205

Underlying: Common Stock · 676,205 shares

Expires 2036-08-05

F4 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months.